Investor pressure pushing drugmakers to make deals
Tuesday’s blockbuster deal involving Indianapolis-based Eli Lilly and Co. was just the latest of several that have taken place since the beginning of the year.
Health Care
Articles
Three more charged in $80M heist of Lilly drugs
Three Florida men who federal authorities say stole about $80 million in prescription drugs from an Eli Lilly and Co. warehouse in Connecticut have been charged with conspiracy and theft.
Lilly to pay dearly for Novartis animal health biz
Wall Street analysts raised their eyebrows at the hefty price Eli Lilly and Co. will pay to acquire Novartis Animal Health, when compared to the value of the biggest player in the field.
Lilly wins approval for potential blockbuster drug
The Indianapolis-based pharmaceutical maker gets a much-needed boost with FDA approval for gastric-cancer drug ramucirumab, which quickly could account for $1 billion in annual sales.
Late sign-ups boost numbers, improve Obamacare outlook
Still to be announced is what share of those 8 million enrollees were previously uninsured, and how many actually secured coverage by paying their first month’s premiums.
Mainstreet aims to help finance nursing home through crowdfunding
Mainstreet Property Group LLC plans to launch a new round of private placement fundraising on April 21 using a website run by Oregon-based CrowdStreet Inc. and a mix of traditional advertising in central Indiana.
Leaders await decision on Indiana Plan expansion
Two of the state's top Republican lawmakers said Tuesday that they would like to see the federal government sign off on an expansion of Medicaid through the state's health care plan for low-income residents.
Downtown Evansville picked for new IU med school
Evansville officials had pushed the location covering nearly six city blocks as a key for downtown redevelopment. The center that could draw some 2,000 health care students.
ANALYSIS: Turner stood to lose big in Statehouse fight
A top Indiana lawmaker, his family and investors in their company risked losing millions in future profits if a proposed ban on construction of new nursing homes in Indiana had become law this year, an Associated Press review has found.
Indiana insurers must make best guesses on 2015 price hikes
Health insurers such as WellPoint Inc. that plan to hike prices on their Obamacare policies more than 10 percent in 2015 will have a much harder time than usual making their case to regulators.
WellPoint spending millions in California ballot battle
WellPoint Inc. is leading companies that have poured $13.4 million into defeating a ballot initiative that would give California regulators the power to reject increases in health policy premiums.
Lilly stock shows little impact from $3B court award
Eli Lilly and Co.’s stock showed little change Tuesday morning in the wake of a federal court decision that saw jurors order the company to pay a massive damage award related to its Actos diabetes medicine.
Ex-owner of troubled dental clinic pleads guilty to tax evasion
The former owner of a central Indiana dental clinic being investigated for Medicaid fraud has been sentenced to two years in federal prison for not paying more than $850,000 in taxes.
Lilly ordered to pay $3 billion in Actos damages
Takeda Pharmaceutical Co. and Eli Lilly and Co. were ordered to pay a combined $9 billion after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S. trial of its kind.
Pfizer, Lilly drugs slow advanced breast cancer in studies
Pfizer Inc., Eli Lilly and Co. and Novartis AG have dug an idea out of the pharmaceutical dustbin to create new medicines that are showing blockbuster potential.
IU Health doctors to do surgeries in Wisconsin
Indiana University Health was chosen by a hospital system in Wisconsin to provide heart, lung, esophagus and aorta surgeries there after the surgeons the hospital system had been using became employed by a competing provider.
CarDon trying to adjust nursing homes to hospitals, insurers, patients
Family-run company is building nursing homes it thinks will be more attractive to residents and staff.
Patent ‘troll’ label gets Congress to ponder what’s in a name
“Troll” is a term without clear definition and yet it’s being used to push Congress and the Supreme Court to curb abusive litigation. Companies including Eli Lilly warn against damaging a centuries-old system designed to promote advances in science and industry.
Would-be Lilly foe wins U.S. panel backing for inhaled insulin
Advisers to the Food and Drug Administration voted 13-1 and 14-0 that the drug, Afrezza, should be approved for Type 1 and Type 2 diabetes, respectively. The FDA doesn’t have to follow the panel’s recommendation.
Indianapolis court backs patent for Lilly cancer drug Alimta
A federal court has upheld the patent that protects Eli Lilly and Co.'s lung-cancer treatment from generic competition until 2022.